Works matching IS 13520504 AND DT 2019 AND VI 26 AND IP 9


Results: 14
    1
    2
    3

    Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.

    Published in:
    Journal of Viral Hepatitis, 2019, v. 26, n. 9, p. 1127, doi. 10.1111/jvh.13132
    By:
    • Lawitz, Eric;
    • Gane, Edward;
    • Feld, Jordan J.;
    • Buti, Maria;
    • Foster, Graham R.;
    • Rabinovitz, Mordechai;
    • Burnevich, Eduard;
    • Katchman, Helena;
    • Tomasiewicz, Krzysztof;
    • Lahser, Fred;
    • Jackson, Beth;
    • Shaughnessy, Melissa;
    • Klopfer, Stephanie;
    • Yeh, Wendy W.;
    • Robertson, Michael N.;
    • Hanna, George J.;
    • Barr, Eliav;
    • Platt, Heather L.;
    • Gordon, Stuart C.;
    • Lawitz, Eric J.
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13

    Genetic variation in FCER1A predicts peginterferon alfa‐2a‐induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B.

    Published in:
    Journal of Viral Hepatitis, 2019, v. 26, n. 9, p. 1040, doi. 10.1111/jvh.13107
    By:
    • Wei, Lai;
    • Pavlovic, Vedran;
    • Bansal, Aruna T.;
    • Chen, Xiaoping;
    • Foster, Graham R.;
    • He, Hua;
    • Kao, Jia‐Horng;
    • Lampertico, Pietro;
    • Liaw, Yun‐Fan;
    • Motoc, Adriana;
    • Papatheodoridis, George V.;
    • Piratvisuth, Teerha;
    • Plesniak, Robert;
    • Wat, Cynthia
    Publication type:
    Article
    14

    Issue Information.

    Published in:
    Journal of Viral Hepatitis, 2019, v. 26, n. 9, p. 1031, doi. 10.1111/jvh.12958
    Publication type:
    Article